Page M D, Bridges L R, Barth J H, McNichol A M, Belchetz P E
Department of Endocrinology, General Infirmary, Leeds, United Kingdom.
J Clin Endocrinol Metab. 1996 Dec;81(12):4484-7. doi: 10.1210/jcem.81.12.8954064.
We present clinical details of a patient with a 20-yr history of amennorhea, a pituitary tumor, elevated PRL levels, and initially undetectable GH. Bromocriptine failed to fully suppress PRL, and there was no tumor shrinkage. Within 7 months of starting bromocriptine treatment, the patient developed clinical and biochemical signs of acromegaly. At surgery, a stem cell adenoma was excised. The mechanisms by which bromocriptine may have resulted in the development of acromegaly in this patient are discussed.
我们报告了一名患者的临床细节，该患者有20年闭经病史、垂体瘤、催乳素（PRL）水平升高，且最初生长激素（GH）检测不到。溴隐亭未能完全抑制PRL，肿瘤也未缩小。在开始溴隐亭治疗的7个月内，患者出现了肢端肥大症的临床和生化体征。手术切除了一个干细胞腺瘤，并讨论了溴隐亭可能导致该患者发生肢端肥大症的机制。
